Typhoid fever: Difference between revisions
Cathylewwho (talk | contribs) No edit summary |
Vincent Chan (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
Diagnosed in 2% of febrile travelers | *Diagnosed in 2% of febrile travelers and caused by ''[[Salmonella]] enterica serotype Typhi'' (formerly ''Salmonella typhi'') ''serotype paratyphi A, B, and C'' | ||
*Endemic in Mexico, Indonesia, Peru, and the Indian subcontinent | |||
*Prior vaccination does not exclude infection | |||
*Incubation period 1-3 weeks with chronic carrier state defined as organism in urine or stool > 12 months | |||
Endemic in Mexico, Indonesia, Peru, and the Indian subcontinent | *Chronic carrier state risk factors: biliary tract abnormalities | ||
Prior vaccination does not exclude infection | |||
Incubation period 1-3 weeks | |||
Chronic carrier state risk factors: biliary tract abnormalities | |||
* | ==Symptoms== | ||
===Classic symptoms=== | |||
*[[Bradycardia]] relative to fever | |||
===Initial symptoms=== | |||
*[[Fever]] | |||
*[[Abdominal Pain]] | |||
*[[Headache]] | |||
===Subsequent symptoms=== | |||
*Chills (rarely rigors) | *Chills (rarely rigors) | ||
*Cough | *Cough | ||
*Abdominal distension | *Abdominal distension | ||
*Constipation (more common than diarrhea) | *Constipation (more common than diarrhea) | ||
*“Rose spots” – truncal light red macular rash (in the 2nd wk) | *“Rose spots” – truncal light red macular rash (in the 2nd wk) | ||
*Hepatosplenomegaly | *Hepatosplenomegaly | ||
*GI bleeding | *GI bleeding | ||
*Transaminitis | *Transaminitis | ||
*Leukopenia with left shift (adults) | *Leukopenia with left shift (adults) | ||
*Leukocytosis (children) | *Leukocytosis (children) | ||
==Diagnosis and Work-Up | ==Diagnosis and Work-Up== | ||
*Blood culture | |||
Blood culture | *Urine culture | ||
*Stool culture | |||
Urine culture | |||
Stool culture | |||
“Rose spot” aspiration | “Rose spot” aspiration | ||
*Bone marrow culture (most sensitive) | |||
*Sensitivity testing for nalidixic acid | |||
==Complications== | |||
*Small-bowel ulceration | |||
*Intestinal perforation | |||
*[[Anemia]] | |||
==Complications | *[[DIC]] | ||
*[[Pneumonia]] | |||
Small-bowel ulceration | *[[Meningitis]] | ||
*[[Myocarditis]] | |||
Intestinal perforation | *[[Cholecystitis]] | ||
*[[Renal Failure]] | |||
Anemia | *Chronic carrier state | ||
DIC | |||
Pneumonia | |||
Meningitis | |||
Myocarditis | |||
Cholecystitis | |||
Renal | |||
Chronic carrier state | |||
Amebic Liver Abscess | ==Differential Diagnosis== | ||
*[[Malaria]] | |||
Infectious enteritis | *[[Typhus]] | ||
*Viral hepatitis | |||
*Amebic Liver Abscess | |||
*Infectious enteritis | |||
==Treatment== | ==Treatment== | ||
| Line 122: | Line 74: | ||
===Adjunctive Therapy=== | ===Adjunctive Therapy=== | ||
If associated delirium, coma, shock, and/or DIC: Dexamethasone 3 mg/kg IV load over 30 minutes, then 1 mg/kg IV every 6 hours x 8 doses | *If associated delirium, coma, shock, and/or [[DIC]]: Dexamethasone 3 mg/kg IV load over 30 minutes, then 1 mg/kg IV every 6 hours x 8 doses | ||
==Disposition== | ==Disposition== | ||
*Admit if any complication | |||
Admit if any complication | |||
==Sources== | ==Sources== | ||
<references/> | <references/> | ||
*Tintinalli et. al. Typhoid Fever. In: Tintinalli et. al. Emergency Medicine A Comprehensive Study Guide. New York, NY: McGraw Hill. 2011. 1082-1084. | |||
Tintinalli et. al. Typhoid Fever. In: Tintinalli et. al. Emergency Medicine A Comprehensive Study Guide. New York, NY: McGraw Hill. 2011. 1082-1084. | *Hohmann, E. Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever . In: UpToDate. Last updated: July 2013. Accessed July 30, 2014. | ||
Hohmann, E. Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever . In: UpToDate. Last updated: July 2013. Accessed July 30, 2014. | |||
==See Also== | ==See Also== | ||
Revision as of 15:24, 12 August 2014
Background
- Diagnosed in 2% of febrile travelers and caused by Salmonella enterica serotype Typhi (formerly Salmonella typhi) serotype paratyphi A, B, and C
- Endemic in Mexico, Indonesia, Peru, and the Indian subcontinent
- Prior vaccination does not exclude infection
- Incubation period 1-3 weeks with chronic carrier state defined as organism in urine or stool > 12 months
- Chronic carrier state risk factors: biliary tract abnormalities
Symptoms
Classic symptoms
- Bradycardia relative to fever
Initial symptoms
Subsequent symptoms
- Chills (rarely rigors)
- Cough
- Abdominal distension
- Constipation (more common than diarrhea)
- “Rose spots” – truncal light red macular rash (in the 2nd wk)
- Hepatosplenomegaly
- GI bleeding
- Transaminitis
- Leukopenia with left shift (adults)
- Leukocytosis (children)
Diagnosis and Work-Up
- Blood culture
- Urine culture
- Stool culture
“Rose spot” aspiration
- Bone marrow culture (most sensitive)
- Sensitivity testing for nalidixic acid
Complications
- Small-bowel ulceration
- Intestinal perforation
- Anemia
- DIC
- Pneumonia
- Meningitis
- Myocarditis
- Cholecystitis
- Renal Failure
- Chronic carrier state
Differential Diagnosis
Treatment
- Consultation with Infectious Disease should be considered since there are increasingly multidrug resistant strains of S. Typhi and coinfection with diseases such as Malaria may complicate treatment. The therapy favors the use of fluorquinolones unless suspected or known resistance.[1]
Antibiotics
Oral therapy with Quinolone Susceptibility:
- Ciprofloxacin 500-750 mg PO q 12 hrs x 14 days
Parenteral Therapy with Quinolone Susceptibility:
- Ciprofloxacin 400 mg IV q 12 hrs x 10 days
Parenteral Therapy with Quinolone Resistance:
if nalidixic acid resistant, can assume fluoroquinolone resistant
- Ceftriaxone 2mg IV q 24 hrs x 14 days
- OR
- Cefixime 10-15 mg/kg IV q 12 hrs x 8 days
Oral Therapy with Quinolone Resistance:
- Azithromycin 1 g PO daily x 5 days
Adjunctive Therapy
- If associated delirium, coma, shock, and/or DIC: Dexamethasone 3 mg/kg IV load over 30 minutes, then 1 mg/kg IV every 6 hours x 8 doses
Disposition
- Admit if any complication
Sources
- Tintinalli et. al. Typhoid Fever. In: Tintinalli et. al. Emergency Medicine A Comprehensive Study Guide. New York, NY: McGraw Hill. 2011. 1082-1084.
- Hohmann, E. Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever . In: UpToDate. Last updated: July 2013. Accessed July 30, 2014.